Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Lu

Showing results (911-920 of 932) with videos related to

Pageof 94
Sort By:
Journal of Human Genetics|April 22, 2020
Y-chromosome evidence confirmed the Kerei-Abakh origin of Aksay KazakhsShao-Qing Wen, Chang Sun, Dan-Lu Song, et al.
Viruses|November 11, 2022
The CD8+ and CD4+ T Cell Immunogen Atlas of Zika Virus Reveals E, NS1 and NS4 Proteins as the Vaccine TargetsHangjie Zhang, Wenling Xiao, Min Zhao, et al.
ACS Central Science|June 4, 2020
An Epoxide Intermediate in Glycosidase CatalysisLukasz F Sobala, Gaetano Speciale, Sha Zhu, et al.
Neurology and Therapy|November 3, 2021
Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort StudyRong-Jing Guo, Ting Gao, Zhe Ruan, et al.
The Lancet. Oncology|May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 studyMaria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
European Journal of Radiology|April 5, 2025
Preoperative identification of hepatocellular carcinoma from focal liver lesions ≤ 20 mm in high-risk patients using clinical and contrast-enhanced ultrasound featuresXin-Yuan Hu, Yi-Kang Sun, Yao Miao, et al.
The Lancet. Haematology|April 3, 2019
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)Franck Morschhauser, Ian W Flinn, Ranjana Advani, et al.
Animal Models and Experimental Medicine|March 19, 2021
SARS-CoV-2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in miceYuanwu Ma, Dan Lu, Linlin Bao, et al.
The American Journal of Cardiology|August 9, 2023
Heart Rate Response Predicts 6-Minutes Walking Distance in Pulmonary Arterial HypertensionDan Lu, Chun-Yan Cheng, Xi-Jie Zhu, et al.
Immunology|September 3, 2022
Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVacXingyu Zhou, Yifan Wang, Bo Huang, et al.
Pageof 94

Showing results (911-920 of 932) with videos related to

Sort By:
Pageof 94
Journal of Human Genetics|April 22, 2020
Y-chromosome evidence confirmed the Kerei-Abakh origin of Aksay KazakhsShao-Qing Wen, Chang Sun, Dan-Lu Song, et al.
Viruses|November 11, 2022
The CD8+ and CD4+ T Cell Immunogen Atlas of Zika Virus Reveals E, NS1 and NS4 Proteins as the Vaccine TargetsHangjie Zhang, Wenling Xiao, Min Zhao, et al.
ACS Central Science|June 4, 2020
An Epoxide Intermediate in Glycosidase CatalysisLukasz F Sobala, Gaetano Speciale, Sha Zhu, et al.
Neurology and Therapy|November 3, 2021
Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort StudyRong-Jing Guo, Ting Gao, Zhe Ruan, et al.
The Lancet. Oncology|May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 studyMaria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
European Journal of Radiology|April 5, 2025
Preoperative identification of hepatocellular carcinoma from focal liver lesions ≤ 20 mm in high-risk patients using clinical and contrast-enhanced ultrasound featuresXin-Yuan Hu, Yi-Kang Sun, Yao Miao, et al.
The Lancet. Haematology|April 3, 2019
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)Franck Morschhauser, Ian W Flinn, Ranjana Advani, et al.
Animal Models and Experimental Medicine|March 19, 2021
SARS-CoV-2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in miceYuanwu Ma, Dan Lu, Linlin Bao, et al.
The American Journal of Cardiology|August 9, 2023
Heart Rate Response Predicts 6-Minutes Walking Distance in Pulmonary Arterial HypertensionDan Lu, Chun-Yan Cheng, Xi-Jie Zhu, et al.
Immunology|September 3, 2022
Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVacXingyu Zhou, Yifan Wang, Bo Huang, et al.
Pageof 94